person · Reporting owner
Bertrand William C JR
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Chief Operating Officer | August 28, 2025 | August 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 329,507 |
Ending reported balance
After 2026-06-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-16 · Grant · Acquired 12,345 · Balance 303,052 F1: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Row 2 · 2026-06-16 · Grant · Acquired 26,455 · Balance 329,507 F2: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F3: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F4: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program.
F2: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F4: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Adaptimmune Therapeutics PLC
Report date August 28, 2025 · Filed August 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares with a nominal value of GBP0.001 per shareSEC Table I · non-derivative | Direct | 986,352 |
Reported balance
After 2025-08-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-28 · Sale · Disposed 207,000 · Balance 986,352 F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer. F2: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs. F3: The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F4: The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.
F2: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs.
F3: The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F4: The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:02 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 39,715 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001291937-26-000003 · wk-form4_1781812963.xml · derivative · entry 3 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,715 Underlying: Common Stock · 39,715 shares Expires 2036-06-16 F3 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F4 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:02 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 26,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001291937-26-000003 · wk-form4_1781812963.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,507 F2 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:02 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 12,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001291937-26-000003 · wk-form4_1781812963.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,052 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| August 28, 2025 Filed Aug 29, 2025 22:25 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleOrdinary Shares with a nominal value of GBP0.001 per share | 207,000 | $0.01 | $2,090.70 |
DisclosureSEC source: 0001104659-25-085820 · tm2524763-1_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986,352 F1 · security: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer. F2 · shares: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs. F3 · price: The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F4 · balance_after: The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:38 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 54,059 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001628280-25-032724 · wk-form4_1750725489.xml · derivative · entry 3 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,059 Underlying: Common Stock · 54,059 shares Expires 2035-06-18 F3 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F4 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:38 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 41,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032724 · wk-form4_1750725489.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,707 F2 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:38 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 19,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032724 · wk-form4_1750725489.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,156 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 22:35 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,074,696 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015746 · tm257186-6_4seq1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,696 Underlying: Ordinary Shares · 1,074,696 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 22:35 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,612,032 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001104659-25-015746 · tm257186-6_4seq1.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,612,032 Underlying: Ordinary Shares · 1,612,032 shares Expires 2035-02-20 F1 · derivative.exercise_price: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029. Read SEC document |
| January 17, 2025 Filed Jan 18, 2025 02:16 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 5,584 | $0.58 | $3,243.19 |
DisclosureSEC source: 0001104659-25-004606 · tm253716-2_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,510 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 191,382 ADSs and RSU-style options and other options covering an aggregate of 13,421,994 ordinary shares of the Issuer. Read SEC document |
| January 15, 2025 Filed Jan 15, 2025 21:15 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 9,803 | $0.57 | $5,634.76 |
DisclosureSEC source: 0001104659-25-003765 · tm253441-1_4seq1.xml · nonDerivative · entry 3 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,756 F7 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F9 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:15 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 5,471 | $0.59 | $3,216.40 |
DisclosureSEC source: 0001104659-25-003765 · tm253441-1_4seq1.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,623 F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:15 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,268 | $0.59 | $2,509.16 |
DisclosureSEC source: 0001104659-25-003765 · tm253441-1_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,845 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:52 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 40,243 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001628280-24-028600 · wk-form4_1718664726.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,243 Underlying: Common Stock · 40,243 shares Expires 2034-06-14 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:52 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 11,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-028600 · wk-form4_1718664726.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,766 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| January 17, 2024 Filed Jan 17, 2024 22:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 13,599 | $0.67 | $9,152.13 |
DisclosureSEC source: 0001104659-24-004560 · tm243270-13_4seq1.xml · nonDerivative · entry 3 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,201 F7 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F9 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer. Read SEC document |
| January 17, 2024 Filed Jan 17, 2024 22:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 5,309 | $0.67 | $3,572.96 |
DisclosureSEC source: 0001104659-24-004560 · tm243270-13_4seq1.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,785 F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 22:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,681 | $0.79 | $3,697.99 |
DisclosureSEC source: 0001104659-24-004560 · tm243270-13_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,023 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is the sale price per ADS. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 565,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004531 · tm243270-12_4seq1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,416 Underlying: Ordinary Shares · 565,416 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,544,432 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-24-004531 · tm243270-12_4seq1.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,544,432 Underlying: Ordinary Shares · 2,544,432 shares Expires 2034-01-15 F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 22:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 5,220 | $0.85 | $4,458.40 |
DisclosureSEC source: 0001104659-24-003745 · tm243270-4_4seq1.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,874 F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 22:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,009 | $0.84 | $3,354.33 |
DisclosureSEC source: 0001104659-24-003745 · tm243270-4_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 49,237 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001628280-23-022555 · wk-form4_1686954576.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,237 Underlying: Common Stock · 49,237 shares Expires 2033-06-15 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 16,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022555 · wk-form4_1686954576.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,743 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:17 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,440 | $1.86 | $8,249.52 |
DisclosureSEC source: 0001104659-23-004381 · tm231655-19_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,264 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 107,907 ADSs and RSU-style options and other options covering an aggregate of 11,162,136 ordinary shares of the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:07 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 202,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004377 · tm231655-16_4seq1.xml · derivative · entry 3 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,800 Underlying: Ordinary Shares · 202,800 shares Expires 2025-03-15 F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:07 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004377 · tm231655-16_4seq1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:07 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001104659-23-004377 · tm231655-16_4seq1.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2033-01-17 F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 02:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,973 | $1.71 | $8,483.94 |
DisclosureSEC source: 0001104659-23-003539 · tm231655-8_4seq1.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,121 F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 93,516 ADSs and RSU-style options and other options covering an aggregate of 9,308,232 ordinary shares of the Issuer. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 02:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,843 | $1.75 | $6,712.95 |
DisclosureSEC source: 0001104659-23-003539 · tm231655-8_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,270 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 93,516 ADSs and RSU-style options and other options covering an aggregate of 9,308,232 ordinary shares of the Issuer. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 02:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,584 | $1.69 | $6,071.30 |
DisclosureSEC source: 0001104659-23-001092 · tm231655-4_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,781 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 87,735 ADSs and RSU-style options and other options covering an aggregate of 9,447,474 ordinary shares of the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001567619-22-013089 · doc1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-15 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 118,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013089 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,162 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 02:04 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,368 | $3.19 | $13,941.78 |
DisclosureSEC source: 0001104659-22-005056 · tm221700-18_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,336 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 80,399 ADSs and RSU-style options and other options covering an aggregate of 9,503,664 ordinary shares of the Issuer. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 02:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 2,248 | $3.54 | $7,967.14 |
DisclosureSEC source: 0001104659-22-004153 · tm221700-14_4seq1.xml · nonDerivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,754 F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 70,302 ADSs and RSU-style options and other options covering an aggregate of 9,573,888 ordinary shares of the Issuer. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 02:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-004148 · tm221700-10_4seq1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 02:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-22-004148 · tm221700-10_4seq1.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2032-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 02:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,770 | $3.56 | $13,408.76 |
DisclosureSEC source: 0001104659-22-004153 · tm221700-14_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,343 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 70,302 ADSs and RSU-style options and other options covering an aggregate of 9,573,888 ordinary shares of the Issuer. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 02:08 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,490 | $4.06 | $14,184.06 |
DisclosureSEC source: 0001104659-22-001671 · tm221700-4_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,873 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,429 ADSs and RSU-style options and other options covering an aggregate of 7,949,250 ordinary shares of the Issuer. Read SEC document |
| July 02, 2021 Filed Jul 3, 2021 00:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 4,375 | $4.26 | $18,658.94 |
DisclosureSEC source: 0001104659-21-089050 · tm2121284-9_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,329 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.26 to $4.30, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 57,100 ADSs and RSU-style options and other options covering an aggregate of 8,005,428 ordinary shares of the Issuer. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:11 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 32,765 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-21-012431 · doc1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,765 Underlying: Common Stock · 32,765 shares Expires 2031-06-16 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:11 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 8,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012431 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,549 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 2,234 | $6.15 | $13,744.01 |
DisclosureSEC source: 0001104659-21-003594 · tm212950-4_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,768 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 53,332 ADSs and RSU-style options and other options covering an aggregate of 8,075,652 ordinary shares of the Issuer. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 02:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 242,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003129 · tm212800-1_4seq1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,712 Underlying: Ordinary Shares · 242,712 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 02:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,086,816 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-21-003129 · tm212800-1_4seq1.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086,816 Underlying: Ordinary Shares · 1,086,816 shares Expires 2031-01-11 F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,499 | $5.33 | $18,642.32 |
DisclosureSEC source: 0001104659-21-001177 · tm211506-3_4seq1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,864 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 47,468 ADSs and RSU-style options and other options covering an aggregate of 6,782,136 ordinary shares of the Issuer. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 15,000 | $7.08 | $106,255.50 |
DisclosureSEC source: 0001567619-20-021092 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,658 F1 · shares: This transaction was executed in multiple trades in prices ranging from $7.08 to $7.10, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F1 · price: This transaction was executed in multiple trades in prices ranging from $7.08 to $7.10, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 02:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | PurchaseOrdinary Shares with a nominal value of GBP0.001 per share | 207,000 | $0.69 | $143,823.60 |
DisclosureSEC source: 0001104659-20-135891 · tm2038497-1_4.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,808 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by William Bertrand. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs. F3 · price: The price reported in Column 4 of $0.6948 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1688 per ADS divided by six. The purchase price per ADS is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $4.14 to $4.17, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs purchased at each separate price within the range set forth in this footnote. F4 · balance_after: The 284,808 ordinary shares reported in Column 5 include 77,808 ordinary shares represented by 12,968 ADSs owned by Mr. Bertrand prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Bertrand. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:34 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-20-012034 · doc1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-09 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:34 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 7,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012034 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,658 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.